| INTRODUCTION
Although the prevalence of premature ovarian insufficiency (POI) varies between different populations, it is encountered in %1-2 of the cases <40 years of age, its prevalence decreases to 0.1% in women <30 years and 0.01% in women younger than 20 years of age.
1
Among all women with POI, some may have cyclic normal ovarian function after diagnosis and 5-10% of the cases were reported to conceive following certain diagnosis.
2,3
Although the exact mechanism of POI has not been clarified, accelerated follicle losses and dysfunction are most commonly proposed etiologies in these cases. 4 Several etiological mechanisms have been introduced up to date, including genetic causes, autoimmune disorders, infections, toxins and iatrogenic causes (pelvic surgery, chemotherapy, radiotherapy). 5, 6 Additionally, estrogen depletion was shown to result in proinflammatory process secondary to the increased pro-inflammatory active metabolites. 7 It is well known that POI is associated with the decreased estrogen levels, and as we mentioned above, decreased estrogen levels lead to increase pro-inflammatory markers; additionally, oral estrogen replacement therapy was shown to result in decreased concentrations of all inflammatory marker.
8-10
Generally POI is diagnosed in women <40 years of age with elevated FSH levels >25 mIU/mL and accompanying 4-6 months of amenorrhea or oligomenorrhea periods.
11
Currently, serum FSH and anti-Mullerian hormone (AMH) levels are utilized to diagnose POI cases. AMH levels were shown to decrease secondary to the decreased antral follicle numbers. 12 Neutrophil/lymphocyte (NLR), platelet/lymphocyte (PLR), RDW/platelet (RPR), and mean platelet volume/lymphocyte ratios have been introduced to be markers for systemic inflammation. These markers were shown to have significant predictive values for the diagnosis and prognosis of some cancers such as papillary thyroid, lung, gastrointestinal cancers, and additionally, most commonly encountered changes secondary to systemic inflammation were shown to be thrombocytopenia and neutrophilia. 13 In this study, we aimed to assess the utility of some complete blood count parameters to predict POI. to examine the relationships between parameters with non-normal distribution. Significance was assessed at P < .05 level.
| MATERIAL AND METHODS

| RESULTS
The basic characteristics and hormone levels of the groups are shown in Table 1 .
The age of the patients ranged from 20 to 39 years, and the mean age was 31.78 ± 4.96 years. There was no statistically significant difference between the groups in terms of age (P > .05).
Prolactin, TSH, glucose, progesterone, red cell distribution width (RDW), number of platelets (PLT), mean platelet volume (MPV), RDW/ PLT, PLT/number of lymphocytes (LYMP), and hematocrit levels (P > .05, for all) were not statistically different between two groups. However, the FSH levels were significantly higher and the AMH levels were lower in the POI group (P < .001, for all) ( Table 1 ). There was statistically significant correlation between FSH and LH in the same direction (positive) 54.1%
(P < .01), but there was no significant correlation between FSH and other parameters (P > .05). There was statistically significant correlation between AMH and FSH in the reverse direction (negative) 30% (P < .01), and statistically significant correlation with white blood cell count (WBC) 23% (P < .05) in the same direction (positive). There was no statistically significant correlation between AMH and other parameters (P > .05).
WBC, number of neutrophil (NEU) and MPV levels between groups
were different, the differences were statistically significant (P < .05, for all). Moreover, the hemoglobin level of POI group was statistically significantly higher (P < .05); LYMP level was statistically significantly lower in POI (P < .05).
The POI group had a mean NLR of 2.08 ± 0.89, an RPR of 0.02, a PLR of 128.64 ± 39.33, and an MPLR of 4.01 ± 1.30. The NLR of the POI group was statistically significantly higher (P < .01). Similarly, the MPLR of patients in the POI group was statistically significantly higher than the mean MPLR (P < .01).
We also performed ROC curve analysis for MPLR in the POI group.
The area under ROC curve for MPLR in POI was 0.60 ( Figure 1) , with a threshold value 3.5 with a sensitivity = 61% and specificity = 53%.
(95% CI: 0.529-0.684; P < .001). 
| DISCUSSION
14,15
The mechanisms that cause or induce ovarian autoimmunity and inflammation in POI etiology are not fully known. 16 It is well known that, during pathogenesis, the biological effects of inflammation are increased, and the ability to adapt to cellular proliferation, inhibition of apoptosis, angiogenesis, oxidative stress is reduced. Platelets were proposed to play an important metabolic role in the background of inflammation due to their angiogenic, metastatic, and proteolytic activities. 17, 18 MPV is also an inflammatory marker that reflects platelet activity. Metabolic and enzymatic activities of the platelets were shown to be related with its volume.
19
The anti-inflammatory and pro-inflammatory effects of estrogens depend on estradiol concentration. During the pathogenesis of POI, the pro-inflammatory pathway becomes active as the body's estrogen concentration decreases, resulting in B-cell activation, TNF, IFNγ, and IL-1β activation in dendritic cells, and also the NK-cell activation.
B-cell activation is a harmful factor in B cell-mediated diseases such as SLE. On the other hand, as the estrogen concentration increases, the anti-inflammatory pathway becomes active. 7 To date, the relationship between many types of cancer and MPV has been investigated.
20-26
All authors reported that MPV could be used as a cheap, non-invasive marker for cancer diagnosis and prognosis in these publications. MPV has also been used as a diagnostic and prognostic marker in active lupus disease as an autoimmune disease. Guillermo et al. reported that MPV was reduced in active lupus adult patients and MPV correlated 
